Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: Yohimbine HCl evidence and protocol review
Also known as: Yohimbine hydrochloride
Yohimbine HCl is an alpha-2 adrenergic receptor antagonist, marketed for fat loss based on its proposed mechanism of blocking alpha-2-receptor-mediated inhibition of lipolysis (particularly in stubborn fat-storage areas). The human evidence is genuinely mixed: one controlled clinical trial found the yohimbine group lost 2.2% body fat versus placebo with no significant change in lean mass, sprint performance, or vertical jump, while a systematic review of 3 high-quality clinical trials on yohimbine for weight reduction found conflicting results and could not conclude that yohimbine is effective - and a separate study found yohimbine had no effect on fat distribution in men compared to controls. This body of evidence should be represented as genuinely unsettled, not as an established fat-loss agent.
Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.
Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Amounts and schedules are separated by administration route. Evidence badges distinguish labels, human studies, preclinical work, community reports, and evidence gaps.
5.4 mg three times daily in older labeled prescription use
Context: archived yohimbine labeling and clinical literature
Formulation: Oral-mucosal formulations are not dose-equivalent to injectable or topical formulations.
Route safety: Non-human or laboratory exposure. It cannot be converted into a human dose.
Do not convert an amount between routes. Bioavailability, formulation, sterility, monitoring, and clinical context differ by route. Research-use context only; independently verify every cited source.
Yohimbine has a narrow safety margin and variable CYP2D6 metabolism. Anxiety, hypertension, tachycardia, and serious toxicity are reported; fat-loss use is unapproved.
Supplementary research context only. Not medical advice or a treatment recommendation.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.